Business Context and Reporting Period
This Form 8-K is a current report filed by Leap Therapeutics, Inc. (trading symbol: LPTX) on November 18, 2019. The registrant is a Delaware corporation listed on the Nasdaq Global Market. The report addresses two primary events: a notification regarding non-compliance with Nasdaq listing standards and the announcement of a new clinical study.
Key Financial Metrics
The filing references the Company's stockholders' equity as reported in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.
- Stockholders' Equity: $5,562,000
- Nasdaq Minimum Requirement: $10,000,000
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for these metrics.
Material Changes and Events
Delisting Notice (Item 3.01)
On November 19, 2019, the Company received a notice from Nasdaq indicating that its stockholders' equity of $5,562,000 fails to meet the minimum requirement of $10,000,000 under Nasdaq Listing Rule 5450(b)(1)(A). The notice has no immediate effect on trading, and the stock continues to trade under the symbol "LPTX."
The Company has 45 calendar days to submit a compliance plan. If accepted, Nasdaq may grant an extension of up to 180 days to regain compliance. There is no assurance that compliance will be achieved.
Clinical Study Announcement (Item 8.01)
On November 18, 2019, the Company announced a planned investigator-initiated clinical study evaluating DKN-01 in combination with Roche's TECENTRIQ (atezolizumab). Key details include:
- Indication: Previously-treated patients with advanced microsatellite stable esophagogastric cancer.
- Conductor: Royal Marsden NHS Foundation Trust.
- Funding: Fully sponsored by Roche, which will also provide TECENTRIQ drug supply.
- Company Contribution: Leap Therapeutics will provide DKN-01 drug supply.
- Enrollment: Up to 52 patients with advanced inoperable or metastatic mismatch repair proficient gastroesophageal adenocarcinoma.
- Endpoints: Safety, tolerability, and objective response rate.
Guidance, Outlook, and Risks
The Company anticipates timely submitting a plan to Nasdaq to regain compliance with listing standards. However, the filing explicitly states there can be no assurance that the Company will be able to regain compliance. If the plan is not accepted or an extension is not granted, the Company may consider appeals to a Nasdaq Listing Qualifications Panel or other appropriate actions.
Investor Verification Checklist
- Verify the Company's submission of a compliance plan to Nasdaq within the 45-day window.
- Monitor the status of the stockholders' equity to determine if it reaches the $10,000,000 threshold.
- Confirm the initiation and enrollment progress of the DKN-01 and TECENTRIQ combination study.
- Review the full Form 10-Q for the quarter ended September 30, 2019, for detailed financial statements not included in this 8-K.